Secondary objectives are to:
1. Evaluate the efficacy of BOR1500L7 on:
- The reduction of ulcerative lesions rates following the prodromal stage;
- The extension of the delay prior to first ulcerative lesions occurence following the prodromal stage;
- The decrease of cumulative ulcerative lesions